AB.PA
AB Science S.A.
Paris
13.23-0.22 (-1.64%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close13.45
Open13.47
Bid13.68 x 10000
Ask13.85 x 30000
52wk Range8.62 - 19.90
Day's Range13.09 - 13.47
Volume57,072
Avg Vol (3m)107,306
As of 11:35 AM EDT. Market closed.
  • TheStreet.com4 months ago

    AB Science Claims ALS Drug Success in Opaque Trial Announcement

    Incomplete information from the AB Science trial makes it difficult to ascertain if ALS patient truly benefited from the company's lead compound masitinib.

  • Bloomberglast year

    France Banned AB Science Drug Studies Because of Side Effects

    The National Agency for Drug Safety , known as ANSM, ordered AB Science Chief Executive Officer Alain Moussy to stop trials of masitinib in Alzheimer’s disease, severe asthma, chronic obstructive pulmonary disease, multiple sclerosis and rheumatoid arthritis and painful bladder syndrome, according to a May 2012 letter from the agency that Bloomberg News obtained this month under France’s public records law.